HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels
Velia Chiara Di Maio(University of Rome Tor Vergata), C. Sarrecchia(University of Rome Tor Vergata), Antonio Di Biagio, Valeria Cento(Rostov State Medical University), Adriano Pellicelli(Carlo Forlanini Hospital), Giuliano Rizzardini, Laura Ambra Nicolini(Ospedale Policlinico San Martino), Loredana Sarmati(University of Rome Tor Vergata), M. Melis(University of Sassari), Simona Landonio(ASST Fatebenefratelli Sacco), Umberto Vespasiani‐Gentilucci(Università Campus Bio-Medico), Claudio Maria Mastroianni(Sapienza University of Rome), Antonio Gasbarrini(Università Cattolica del Sacro Cuore), M. Aragri(University of Rome Tor Vergata), A. Picciotto(Fondazione Bruno Kessler), C. Pasquazzi(Azienda Ospedaliera Sant'Andrea), Monica Tontodonati(Azienda USL di Pescara), Chiara Baiguera(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Sergio Babudieri(University of Sassari), S. Francioso, Ada Bertoli(IRCCS Policlinico San Donato), Marco Romano(University of Campania "Luigi Vanvitelli"), Giuseppe Tisone, L. Lambiase, Gloria Taliani(Sapienza University of Rome), M. Angélico, Massimo Andreoni(University of Rome Tor Vergata), Dante Romagnoli(University of Modena and Reggio Emilia), F.P. Antonucci(University of Rome Tor Vergata), L. Nosotti, I. Lenci(University of Rome Tor Vergata), Francesca Ceccherini‐Silberstein(University of Cologne), Giustino Parruti(Azienda USL di Pescara), Valeria Micheli(ASST Fatebenefratelli Sacco), Maria Concetta Bellocchi(University of Rome Tor Vergata), Savino Bruno(Humanitas University), Stefano Marenco(National Institutes of Health), Jacopo Vecchiet(University of Chieti-Pescara), Carlo Federico Perno(Centre International De Reference Chantal Biya), Martina Milana(University of Rome Tor Vergata), Valerio Giannelli(Sapienza University of Rome), M.S. Mura(University of Sassari), F. De Leonardis(University of Rome Tor Vergata), Laura Gianserra(Azienda Ospedaliera Sant'Andrea), Vincenzo Vullo(Policlinico Umberto I), C. Magni(ASST Fatebenefratelli Sacco), Filomena Morisco, Massimo Siciliano(Università Cattolica del Sacro Cuore)
Cited by 13
Related Papers
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
Commensal Clostridia: leading players in the maintenance of gut homeostasis
|Gut Pathogens|2013|753
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Comprehensive approach for correction of motion and distortion in diffusion‐weighted MRI
|Magnetic Resonance in Medicine|2003|547